Given its rarity, drug-related hepatotoxicity may not be seen during the initial clinical trials of
a new medication. After approval, when many more patients are exposed, toxic effects that
are very infrequent may emerge. This review explains the difficulties in identifying the cause
of hepatotoxic effects in such situations and provides clinical guidance with regard to the
detection, evaluation, and possible prevention of drug-related hepatotoxicity.